|
GB0012528D0
(en)
*
|
2000-05-23 |
2000-07-12 |
Univ Palackeho |
Triterpenoid derivatives
|
|
GB0219052D0
(en)
*
|
2002-08-15 |
2002-09-25 |
Cyclacel Ltd |
New puring derivatives
|
|
GB0226583D0
(en)
*
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
|
GB0229581D0
(en)
*
|
2002-12-19 |
2003-01-22 |
Cyclacel Ltd |
Use
|
|
CN1897950A
(zh)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
稠合芳基和杂芳基衍生物及其使用方法
|
|
EP1694686A1
(en)
|
2003-12-19 |
2006-08-30 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
WO2006023931A2
(en)
|
2004-08-18 |
2006-03-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
EP2343303A1
(de)
|
2004-10-07 |
2011-07-13 |
Boehringer Ingelheim International GmbH |
PI3-Kinase Inhibitoren
|
|
EP1812439B2
(en)
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
DE102005048072A1
(de)
*
|
2005-09-24 |
2007-04-05 |
Bayer Cropscience Ag |
Thiazole als Fungizide
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
|
DE102006001161A1
(de)
*
|
2006-01-06 |
2007-07-12 |
Qiagen Gmbh |
Verfahren zum Nachweis von Cytosin-Methylierungen
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20070238746A1
(en)
*
|
2006-04-06 |
2007-10-11 |
Trixi Brandl |
Thiazolyl-dihydro-chinazoline
|
|
US7691868B2
(en)
*
|
2006-04-06 |
2010-04-06 |
Boehringer Ingelheim International Gmbh |
Thiazolyl-dihydro-quinazoline
|
|
US7517995B2
(en)
|
2006-04-06 |
2009-04-14 |
Boehringer Ingelheim International Gmbh |
Thiazolyl-dihydro-cyclopentapyrazole
|
|
AU2007238690B2
(en)
*
|
2006-04-12 |
2013-05-02 |
Vertex Pharmaceuticals Incorporated |
4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
|
|
EP2382975A3
(en)
|
2006-05-09 |
2012-02-29 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
|
SG158147A1
(en)
|
2006-10-09 |
2010-01-29 |
Takeda Pharmaceutical |
Kinase inhibitors
|
|
ATE510827T1
(de)
|
2007-10-12 |
2011-06-15 |
Ingenium Pharmaceuticals Gmbh |
Inhibitoren von proteinkinasen
|
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
|
US8389533B2
(en)
*
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
|
JP5579724B2
(ja)
*
|
2008-10-17 |
2014-08-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
AU2010268058A1
(en)
|
2009-07-02 |
2012-01-19 |
Novartis Ag |
2-carboxamide cycloamino ureas useful as PI3K inhibitors
|
|
EP2545037A1
(en)
|
2010-03-10 |
2013-01-16 |
Ingenium Pharmaceuticals GmbH |
Inhibitors of protein kinases
|
|
US9498471B2
(en)
|
2011-10-20 |
2016-11-22 |
The Regents Of The University Of California |
Use of CDK9 inhibitors to reduce cartilage degradation
|
|
CA3000633C
(en)
|
2014-10-14 |
2023-10-03 |
The Regents Of The University Of California |
Use of cdk9 and brd4 inhibitors to inhibit inflammation
|
|
US20170283445A1
(en)
|
2016-04-05 |
2017-10-05 |
University Of South Carolina |
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
|
|
US12428423B2
(en)
|
2017-04-01 |
2025-09-30 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
|
|
CN111094291B
(zh)
*
|
2017-08-11 |
2022-06-21 |
晟科药业（江苏）有限公司 |
1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
|
|
US11162083B2
(en)
|
2018-06-14 |
2021-11-02 |
University Of South Carolina |
Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
US12312355B2
(en)
|
2019-08-02 |
2025-05-27 |
Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. |
1H-[1, 2, 3]triazolo[4, 5-h] quinazoline compounds acting as protein kinase inhibitors
|
|
CA3150681A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
US11851426B2
(en)
|
2019-10-11 |
2023-12-26 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CN116096721B
(zh)
*
|
2020-08-27 |
2026-01-09 |
晟科药业（江苏）有限公司 |
作为新型选择性flt3抑制剂的1h-咪唑并[4,5-h]喹唑啉化合物
|
|
US12559733B2
(en)
|
2020-10-22 |
2026-02-24 |
University Of South Carolina |
Optimization of type IV BRAF inhibitors for the treatment of melanoma
|
|
US20230416271A1
(en)
*
|
2020-11-26 |
2023-12-28 |
Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. |
Heteroarylquinazoline compounds as protein kinase inhibitors
|
|
US20240309004A1
(en)
*
|
2021-01-29 |
2024-09-19 |
Virokyne Therapeutics, Llc |
Selective cyclin-dependent kinase inhibitors and methods of therapeutic use thereof
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CN121368595A
(zh)
*
|
2023-06-01 |
2026-01-20 |
成都赛璟生物医药科技有限公司 |
1h-[1,2,3]三唑并[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|